CEO: We Want to Digitize Biotech
Zymeworks Inks $187M Merck Deal for Bi-Specific Antibodies
By Jennifer Boggs
Tuesday, August 30, 2011
Privately held Zymeworks Inc. emerged from stealth mode this week, with its first major commercialization deal matching up its bispecific antibody technology with drug development at Merck & Co. Inc. in the areas of oncology and autoimmune diseases.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.